COMPANY
Auritec Pharmaceuticals
Funding and NIH signals
- NIH award NIH awarded $1.03M (SBIR Phase II 1R44AG102256-01, new, notice Sep 17, 2026). NIH RePORTER 1R44AG102256-01 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 1R44AG102256-01
Organization: AURITEC PHARMACEUTICALS, INC.; City/State: PASADENA, CA; Project number: 1R44AG102256-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1029519; Administering IC: National Institute on Aging; Project title: Long-acting Injectable Brexpiprazole for Agitation in Alzheimer's Dementia; Organization type: Domestic For-Profits
- Sep 17, 2026 · NIH RePORTER 1R44AG102256-01